CAGE Bio Inc., an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology based in San Carlos, California and Fort Worth, on Feb. 16 announced the closing of a $7.2 million over-subscribed Series A financing. The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and […]
Want to Read More?
TBP Insiders get unlimited access to all Insider content and much more.
Already an Insider? log in